Plus Therapeutics to Attend Jones Trading Healthcare Summit and ThinkEquity Conference

Plus Therapeutics, a clinical-stage pharmaceutical company specializing in targeted radiotherapeutics for central nervous system cancers, has announced its participation in two upcoming healthcare conferences. The company’s management team will be attending the Jones Trading 2023 Healthcare Summit from October 9-11, 2023, in Miami Beach, FL. Additionally, Plus Therapeutics’ President and CEO, Marc H. Hedrick, M.D., will be presenting and holding one-on-one investor meetings at the ThinkEquity Conference on October 19, 2023, in New York, NY.

The Jones Trading 2023 Healthcare Summit will provide an opportunity for Plus Therapeutics to engage in one-on-one meetings with investors. The event, held at the Eden Roc Miami Beach, will offer a platform for the company to discuss its innovative platform technologies and advancements in targeted radiotherapeutics for central nervous system cancers. Interested parties can register for the summit through the provided link.

Following the Jones Trading Healthcare Summit, Plus Therapeutics will participate in the ThinkEquity Conference. Dr. Marc H. Hedrick, a respected figure in the field, will deliver a corporate presentation and engage in one-on-one investor meetings. The conference will take place at the Mandarin Oriental in New York and will be webcasted for broader accessibility. Interested individuals can register for the webcast through the provided link.

Plus Therapeutics is focused on developing targeted radiotherapeutics that have the potential to enhance clinical outcomes for patients with difficult-to-treat central nervous system cancers. By combining image-guided local beta radiation and targeted drug delivery approaches, the company aims to address the unmet medical needs in recurrent glioblastoma and leptomeningeal metastases. Plus Therapeutics has established strategic partnerships to support the development, manufacturing, and potential commercialization of its products.

With operations in key cancer clinical development hubs including Austin and San Antonio, Texas, Plus Therapeutics benefits from an experienced and dedicated leadership team. The company’s commitment to advancing its pipeline of product candidates demonstrates its dedication to improving the lives of patients with central nervous system cancers.

Cautionary Statement Regarding Forward-Looking Statements:
This press release contains forward-looking statements, which are subject to various risks and uncertainties that may cause actual results to differ materially. Factors that could cause such differences include the early stage of the company’s product candidates, the outcome of clinical trials, market conditions, and competition within the cancer diagnostics and therapeutics field. The company assumes no obligation to update or revise any forward-looking statements.

Investors interested in scheduling one-on-one meetings with the Plus Therapeutics management team during the conferences are encouraged to contact their Jones or ThinkEquity representative.

For more information about Plus Therapeutics and its innovative approach to targeted radiotherapeutics, please visit their website at https://plustherapeutics.com/.